"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
| Descriptor ID |
D015282
|
| MeSH Number(s) |
D04.345.566.650 D12.644.641.650
|
| Concept/Terms |
SMS 201-995- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
|
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
-
Samson SL, Nachtigall LB, Fleseriu M, Jensterle M, Manning PJ, Elenkova A, Molitch ME, Ludlam WH, Patou G, Haviv A, Biermasz NR, Giustina A, Strasburger CJ, Kennedy L, Melmed S. Durable biochemical response and safety with oral octreotide capsules in acromegaly. Eur J Endocrinol. 2022 Dec 01; 187(6):733-741.
-
Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B. Network meta-analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster. Headache. 2022 04; 62(4):482-511.
-
Shah SM, Nguyen QD, Mir HS, Polito A, Hafiz G, Tatlipinar S, Do DV, Vitale S, Haller JA. A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema. Retina. 2010 Jan; 30(1):160-6.
-
Sass DA, Chopra KB. Portal hypertension and variceal hemorrhage. Med Clin North Am. 2009 Jul; 93(4):837-53, vii-viii.
-
Hanaoka H, Tominaga H, Yamada K, Paudyal P, Iida Y, Watanabe S, Paudyal B, Higuchi T, Oriuchi N, Endo K. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med. 2009 Aug; 23(6):559-67.
-
Pelletier GJ. Invited commentary. Ann Thorac Surg. 2006 Nov; 82(5):1656-7.
-
Krakauer EL, Zhu AX, Bounds BC, Sahani D, McDonald KR, Brachtel EF. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups. N Engl J Med. 2005 Feb 24; 352(8):817-25.
-
Au M, Weber TR, Fleming RE. Successful use of somatostatin in a case of neonatal chylothorax. J Pediatr Surg. 2003 Jul; 38(7):1106-7.
-
Nyquist GG, Hagr A, Sobol SE, Hier MP, Black MJ. Octreotide in the medical management of chyle fistula. Otolaryngol Head Neck Surg. 2003 Jun; 128(6):910-1.
-
Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot. 2002 Nov; 57(5):749-63.